Bovax Awarded the Title of Innovative Small and Medium-sized Enterprise

Recently, the Shanghai Municipal Commission of Economy and Informatization published the list of Shanghai Innovative Small and Medium-Sized enterprises in 2023 (the fourth releasing), where our company was awarded the title of "Innovative Small and Medium-Sized Enterprise" in Shanghai.

Bovax has mastered the international advanced genetic engineering recombinant Virus-Like Particles technology (VLPs technology), and has established a technology platform for the expression of VLPs with innovative Hasenula polymorpha expression system as the core technololgy. Based on the VLP technology platform, Bovax has several research pipeline. The 4-valent HPV vaccine and 9-valent HPV vaccine are in Phase III clinical stage. The 15-valent HPV vaccine has been approved for clinical trials. The recombinant EV71 vaccine is in Phase I clinical stage. Among them, Bova's 9-valent HPV vaccine is the first 9-valent HPV candidate vaccine entering Phase III clinical trials in China. In 2015, Bovax began the R&D of therapeutic drugs for diabetes.

The core team of Bovax consists of several senior vaccine researchers who have extensive experience in vaccine R&D and production. Their professional abilities cover a wide range of areas including project management, project design, process research, quality research, production, clinical studies, and strategic cooperation. Bovax places a strong emphasis on intellectual property protection, and actively applies for patents and promotes their applications in scientific and technological achievements. Currently, Bovax holds 13 granted patents. It is expected that Bovax will successively submit the marketing authorization application for recombinant protein vaccines and drugs within the next 5 years.